Haisco Pharmaceutical Group Co., Ltd. (002653.SZ)
CNY 42.8
(-0.23%)
CNY 42.8
(-0.23%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 295.11 Million CNY | -24.65% |
| 2022 | 391.64 Million CNY | -24.33% |
| 2021 | 517.58 Million CNY | -18.7% |
| 2020 | 636.62 Million CNY | 28.9% |
| 2019 | 493.89 Million CNY | 48.21% |
| 2018 | 333.22 Million CNY | 40.28% |
| 2017 | 237.55 Million CNY | -47.53% |
| 2016 | 452.72 Million CNY | 21.65% |
| 2015 | 372.15 Million CNY | -17.4% |
| 2014 | 450.54 Million CNY | -13.23% |
| 2013 | 519.21 Million CNY | 17.19% |
| 2012 | 443.06 Million CNY | 41.87% |
| 2011 | 312.29 Million CNY | 2.14% |
| 2010 | 305.75 Million CNY | 7.77% |
| 2009 | 283.71 Million CNY | 45.43% |
| 2008 | 195.08 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 217.1 Million CNY | 198.38% |
| 2024 Q1 | 91.95 Million CNY | -2.56% |
| 2024 Q2 | 72.76 Million CNY | -20.87% |
| 2023 Q4 | 94.36 Million CNY | -24.91% |
| 2023 FY | 295.11 Million CNY | -24.65% |
| 2023 Q1 | 28.74 Million CNY | -90.06% |
| 2023 Q2 | 46.32 Million CNY | 61.14% |
| 2023 Q3 | 125.66 Million CNY | 171.27% |
| 2022 FY | 391.64 Million CNY | -24.33% |
| 2022 Q2 | 43.61 Million CNY | 66.46% |
| 2022 Q4 | 289.14 Million CNY | 770.16% |
| 2022 Q3 | 33.22 Million CNY | -23.82% |
| 2022 Q1 | 26.2 Million CNY | -62.55% |
| 2021 Q3 | -45.16 Million CNY | -236.85% |
| 2021 Q4 | 69.95 Million CNY | 254.88% |
| 2021 FY | 517.58 Million CNY | -18.7% |
| 2021 Q1 | 287.26 Million CNY | 22.82% |
| 2021 Q2 | 33 Million CNY | -88.51% |
| 2020 Q4 | 233.88 Million CNY | 34.25% |
| 2020 Q1 | 128.37 Million CNY | 15.97% |
| 2020 Q3 | 174.21 Million CNY | 73.97% |
| 2020 FY | 636.62 Million CNY | 28.9% |
| 2020 Q2 | 100.14 Million CNY | -21.99% |
| 2019 Q1 | 49.82 Million CNY | 65.7% |
| 2019 Q3 | 148.35 Million CNY | -19.81% |
| 2019 Q4 | 110.69 Million CNY | -25.39% |
| 2019 FY | 493.89 Million CNY | 48.21% |
| 2019 Q2 | 185.01 Million CNY | 271.34% |
| 2018 Q2 | 85.59 Million CNY | 43.23% |
| 2018 Q4 | 30.06 Million CNY | -80.95% |
| 2018 FY | 333.22 Million CNY | 40.28% |
| 2018 Q1 | 59.76 Million CNY | 146.16% |
| 2018 Q3 | 157.79 Million CNY | 84.34% |
| 2017 Q1 | 44.35 Million CNY | -68.56% |
| 2017 FY | 237.55 Million CNY | -47.53% |
| 2017 Q2 | 94.09 Million CNY | 112.14% |
| 2017 Q4 | 24.27 Million CNY | -67.55% |
| 2017 Q3 | 74.82 Million CNY | -20.49% |
| 2016 Q3 | 73.98 Million CNY | -62.17% |
| 2016 Q1 | 42.05 Million CNY | -55.52% |
| 2016 Q4 | 141.09 Million CNY | 90.71% |
| 2016 FY | 452.72 Million CNY | 21.65% |
| 2016 Q2 | 195.58 Million CNY | 365.02% |
| 2015 Q4 | 94.56 Million CNY | 50.45% |
| 2015 Q3 | 62.85 Million CNY | -45.45% |
| 2015 Q2 | 115.21 Million CNY | 15.76% |
| 2015 Q1 | 99.52 Million CNY | 5.9% |
| 2015 FY | 372.15 Million CNY | -17.4% |
| 2014 Q2 | 150.37 Million CNY | 85.03% |
| 2014 FY | 450.54 Million CNY | -13.23% |
| 2014 Q4 | 93.98 Million CNY | -24.76% |
| 2014 Q3 | 124.91 Million CNY | -16.93% |
| 2014 Q1 | 81.26 Million CNY | -50.27% |
| 2013 Q2 | 146.13 Million CNY | 80.54% |
| 2013 Q4 | 163.42 Million CNY | 26.96% |
| 2013 FY | 519.21 Million CNY | 17.19% |
| 2013 Q1 | 80.94 Million CNY | -44.82% |
| 2013 Q3 | 128.71 Million CNY | -11.92% |
| 2012 FY | 443.06 Million CNY | 41.87% |
| 2012 Q2 | 108 Million CNY | 33.12% |
| 2012 Q3 | 107.25 Million CNY | -0.69% |
| 2012 Q4 | 146.67 Million CNY | 36.75% |
| 2012 Q1 | 81.12 Million CNY | -26.9% |
| 2011 FY | 312.29 Million CNY | 2.14% |
| 2011 Q4 | 110.97 Million CNY | 44.48% |
| 2011 Q3 | 76.81 Million CNY | 3.41% |
| 2011 Q2 | 74.28 Million CNY | 47.9% |
| 2011 Q1 | 50.22 Million CNY | -51.72% |
| 2010 Q3 | 80.21 Million CNY | 0.0% |
| 2010 FY | 305.75 Million CNY | 7.77% |
| 2010 Q4 | 104.03 Million CNY | 29.68% |
| 2009 FY | 283.71 Million CNY | 45.43% |
| 2008 FY | 195.08 Million CNY | 0.0% |